Journal of Advanced Research ( IF 11.4 ) Pub Date : 2022-05-27 , DOI: 10.1016/j.jare.2022.05.006 Xiangjun Kong 1 , Huali Zuo 2 , Hsien-Da Huang 3 , Qianru Zhang 4 , Jiayu Chen 5 , Chengwei He 6 , Yuanjia Hu 1
|
Background
The STimulator of INterferon Genes (STING) plays an essential role in the innate immune system by inducing the expression of type I interferons (IFNs) and inflammatory cytokines upon sensing cytosolic DNA. Although modulating STING has shown promise as a potential treatment for cancers and inflammatory and autoimmune diseases in substantial pre-clinical studies, current preliminary clinical results of STING agonists have demonstrated limited anti-tumor efficacy. Currently, there is ongoing R&D targeting STING and focusing on the delivery of next-generation therapeutics. Whereas no comprehensive analysis on the STING patent landscape has been conducted to fill the gap between basic research progress and drug development and commercialization.
Aim of review
This study summarized the current agents in the clinical stage and global patenting profiles to help identify the current status, development trends, and emerging technologies of the nascent field of STING modulation.
Key scientific concepts of review
Rapidly increasing R&D efforts and outcomes targeting STING were indicated by the recently increasing number and pharmacologic classes of drug candidates in clinic as well as in emergent technological patenting activities. Despite the overall fragmental ownership of patents, several pioneers that have advanced the clinical evaluation of novel STING agonists have established the basis of STING-relevant inventions through their influential patents in the field. These patents also facilitated progress on novel STING modulators, relevant delivery systems, pharmaceutical compositions, and combination strategies with the potential for further enhancing therapeutic outcomes by targeting STING.
中文翻译：
STING 作为药物发现的新兴治疗靶点：来自全球专利格局的观点
背景
干扰素基因刺激因子 (STING) 在先天免疫系统中发挥着重要作用，它通过感应胞质 DNA 诱导 I 型干扰素 (IFN) 和炎性细胞因子的表达。尽管在大量临床前研究中，调节 STING 已显示出有望成为癌症、炎症和自身免疫性疾病的潜在治疗方法，但目前 STING 激动剂的初步临床结果表明其抗肿瘤功效有限。目前，正在进行针对 STING 的研发，并专注于提供下一代疗法。鉴于尚未对 STING 专利格局进行全面分析，以填补基础研究进展与药物开发和商业化之间的差距。
审查目的
本研究总结了目前处于临床阶段的药物和全球专利申请概况，以帮助确定新兴的 STING 调制领域的现状、发展趋势和新兴技术。
综述的关键科学概念
最近临床候选药物数量和药理学类别的增加以及新兴技术专利活动表明，针对 STING 的研发工作和成果正在迅速增加。尽管专利的总体所有权是零散的，但推进新型 STING 激动剂临床评估的几位先驱已经通过他们在该领域具有影响力的专利建立了 STING 相关发明的基础。这些专利还促进了新型 STING 调节剂、相关递送系统、药物组合物和组合策略的进展，并有可能通过靶向 STING 进一步提高治疗效果。
京公网安备 11010802027423号